Skip to main content

Table 1 Baseline patient and disease characteristics in carfilzomib-treated patients reporting a cardiac or vascular-related adverse event

From: Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

  Patients N = 12
Age, median years (range) 59 (49–77)
Male sex, % 50
Durie-Salmon stage at diagnosis  
IA 3
IIA 1
IIIA 7
IIIB 1
ISS stage at diagnosis  
I 0
II 3
III 3
Unknown 6
Lines of previous anti-MM therapy, median 5
Prior bortezomib, n (%) 11 (92)
Prior autologous stem cell transplant, n (%) 9 (75)
Prior anthracycline, n (%) 3 (25)
  1. ISS, International Staging System; MM, multiple myeloma.